About Us

SphingoTec GmbH develops innovative biomarkers for diagnosis, prediction and monitoring of acute medical conditions, such as acute heart failure, acute kidney injury and circulatory shock, in order to support patient management and provide guidance for treatment strategies. Furthermore, sphingotec develops biomarkers for the prediction of health risks, such as obesity, cardiovascular diseases and breast cancer, in order to support prevention strategies. Read More...

A UNIQUE WAY OF DISCOVERING DIAGNOSTIC MARKERS AND THERAPEUTIC TARGETS


SPHINGOTEC GROUP

COMBINING INNOVATIVE BIOMARKER WITH OUTSTANDING TECHNOLOGY

Sphingotec GmbH Logo
NexusDX

 

LATEST NEWS

  • Hitado GmbH becomes Nexus IB10 distributor for sphingotec in Germany and Switzerland

    Hitado GmbH becomes Nexus IB10 distributor for sphingotec in Germany and Switzerland

  • sphingotec launches IVD test for kidney function biomarker penKid® on Nexus IB10 POCT platform

    sphingotec launches IVD test for kidney function biomarker penKid® on Nexus IB10 POCT platform

  • sphingotec transforms into end-to-end diagnostic solutions provider and exclusively represents Nexus Dx IB10 immunoassay portfolio

    sphingotec transforms into end-to-end diagnostic solutions provider and exclusively represents Nexus Dx IB10 immunoassay portfolio

  • sphingotec’s endothelial function biomarker bio-ADM® predicts need for organ support in general ICU patient population

    sphingotec’s endothelial function biomarker bio-ADM® predicts need for organ support in general ICU patient population


 

BIOMARKER

Sphingotest penKid
sphingotest® penKid®
Sphingotest bio-ADM
sphingotest® bio-ADM®

 

A UNIQUE WAY OF DISCOVERING DIAGNOSTIC MARKERS AND THERAPEUTIC TARGETS

 

OUR PARTNERS

 

Top